The Impact of Ezetimibe on Endothelial Function and Other Markers of Cardiovascular Risk

Objective: To review the published literature characterizing the impact of ezetimibe-containing lipid-lowering regimens on endothelial function and other markers of cardiovascular risk and discuss the potential relevance of these effects to the clinical benefit of ezetimibe. Data Sources: A MEDLINE...

Full description

Saved in:
Bibliographic Details
Published in:The Annals of pharmacotherapy 2009-12, Vol.43 (12), p.2021-2030
Main Authors: Bass, Almasa, Hinderliter, Alan L, Lee, Craig R
Format: Article
Language:English
Subjects:
Animals
Anticholesteremic Agents - pharmacology
Azetidines - pharmacology
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Clinical Trials as Topic
Endothelium, Vascular - drug effects
Endothelium, Vascular - metabolism
Ezetimibe
Humans
Hypercholesterolemia - drug therapy
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To review the published literature characterizing the impact of ezetimibe-containing lipid-lowering regimens on endothelial function and other markers of cardiovascular risk and discuss the potential relevance of these effects to the clinical benefit of ezetimibe. Data Sources: A MEDLINE search (2000–August 2009) was completed using the key words ezetimibe, statins, endothelial function, flow-mediated dilation, pleiotropic, and inflammation to identify relevant literature. Bibliographies of identified literature were reviewed for additional references. Study Selection and Data Extraction: All clinical studies published in English that evaluated the effect of ezetimibe on ancillary endpoints of cardiovascular disease risk, including endothelial function, inflammation, thrombosis, and oxidative stress, were evaluated. Data Synthesis: Recent studies in patients with coronary artery disease (CAD), heart failure, and hypercholesterolemia have demonstrated that treatment with ezetimibe for 4–12 weeks elicits no improvement of endothelial function or other measures of cardiovascular disease risk. In contrast, other studies have reported that ezetimibe improves endothelial function in certain patient populations, including those with rheumatoid arthritis, CAD with type 2 diabetes, and metabolic syndrome. However, the statin monotherapy comparator groups in these studies that yielded equivalent reductions in cholesterol were superior, or at least equivalent to, ezetimibe-containing regimens in the improvement of these ancillary endpoints. Conclusions: Overall, the evidence to date suggests that administration of ezetimibe, either as monotherapy or in combination with a statin, exerts minimal beneficial effects on endothelial function and other ancillary measures of cardiovascular disease risk beyond those conferred by its cholesterol-lowering effects. Studies with larger sample sizes and follow-up beyond 12 weeks remain necessary to further define the impact of ezetimibe on the processes integral to the pathogenesis and progression of cardiovascular disease.
ISSN:1060-0280
1542-6270
DOI:10.1345/aph.1M302